Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortality

Canadian Journal of Urology

Volumn 18, Issue 6, 2011, Pages 6018-6024

  van Leeuwen, Pim J ^a   van den Bergh, Roderick C N ^a   Wolters, Tineke ^a   Zhu, Xiaoye ^a   Bul, Meelan ^a   Schröder, Fritz H ^a   Bangma, Chris H ^a   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

DRE; Early detection; Prostate cancer; PSA; Risk; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; FOLLOW UP; HUMAN; INCIDENCE; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEEDLE BIOPSY; NETHERLANDS; PREDICTIVE VALUE; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TUMOR SEEDING;

AGED; BIOPSY, NEEDLE; EARLY DIAGNOSIS; ENDOSONOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM SEEDING; NETHERLANDS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE;

EID: 84860231221     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320-1328.
2. Roobol MJ, Kerkhof M, Schroder FH et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009;56(4):584-591.
3. Hugosson J, Carlsson S, Aus G et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11(8):725-732.
4. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997;157(1):199-202;discussion 202-203.
5. Roobol MJ, Schroder FH. European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int 2003;92(Suppl 2):117-122.
6. D'Amico AV, Whittington R, Malkowicz SB et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001;166(6):2185-2188.
7. De Koning HJ, Blom J, Merkelbach JW et al. Determining the cause of death in randomized screening trial(s) for prostate cancer. BJU Int 2003;92(Suppl 2):71-78.
8. Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95(12):868-878.
9. Thompson IM, Ankerst DP, Chi C et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98(8):529-534.
10. Roobol MJ, Steyerberg EW, Kranse R et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57(1):79-85.
11. Hernandez DJ, Han M, Humphreys EB et al. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int 2009;103(5):609-614.
12. Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, Catalona WJ. Characteristics of prostate cancer detected by digital rectal examination only. Urology 2007;70(6):1117-1120.
13. van Leeuwen P, van den Bergh R, Wolters T, Schroder F, Roobol M. Screening: should more biopsies be taken in larger prostates? BJU Int 2009;104(7):919-924.
14. Briganti A, Chun FK, Suardi N et al. Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer 2007;43(18):2669-2677.
15. Freedland SJ, Isaacs WB, Platz EA et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol 2005;23(30):7546-7554.
16. Holt SK, Salinas CA, Stanford JL. Vasectomy and the risk of prostate cancer. J Urol 2008;180(6):2565-2567; discussion 2567-2568.
17. Stanford JL, Wicklund KG, McKnight B, Daling JR, Brawer MK. Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999;8(10):881-886.
18. Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. Eur Urol 2010;58(2):275-280.
19. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351(2):125-135.
20. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294(4):440-447.